Recent advances in the treatment of neuropathies.
J. Ravits
1998-04-01
Western Journal of Medicine
Abstract:Parkinson's disease and can delay the need for levodopa by one or more years. As monotherapy, pramipexole and ropinirole are largely devoid of the adverse effects that frequently complicate treatment with levodopa, namely motor fluctuations (in the most severe form known as "on-off') and dyskinesia (involuntary choreic movements). Pramipexole and ropinirole are also used with levodopa in more advanced patients to prolong the response to each dose of levodopa and to reduce the trough severity of parkinsonism. Both new agonists are well tolerated but can have adverse effects that resemble those of other dopaminergic agents, such as nausea, dizziness, orthostatic hypotension, confusion, and hallucinations. In conjunction with levodopa, they can cause dyskinesia. Because pramipexole and ropinirole are not ergot derivatives, they may lack rare adverse effects such as retroperitoneal and pulmonary fibrosis associated with the older dopamine agonists. Direct comparisons among the new and old dopamine agonists are scant, but some studies suggest that ropinirole and pramipexole may be superior to bromocriptine. Tolcapone and entacapone, inhibitors of catechol-Omethyl transferase (COMT), will be introduced in the near future; Tolcapone is FDA approved. These drugs block 0-methylation of levodopa to an inert compound, thereby slowing clearance of levodopa from plasma and increasing the amount of levodopa entering the brain, which enhances the response to levodopa. Their effect is somewhat like controlled-release levodopa. The COMT inhibitors have no clinical effect unless they are combined with levodopa. The side effects of tolcapone and entacapone alone are diarrhea. In combination with levodopa, the adverse effects are the same as those of excessive levodopa, so it is often necessary to reduce the levodopa dose. Protective therapies to slow the degeneration of dopaminergic neurons remain at the forefront of scientists' and clinicians' minds. Selegiline, a selective, irreversible MAO-B inhibitor, was widely adopted following the Parkinson's Study Group report that it delayed the need to start levodopa by over a year. The initial enthusiasm for selegiline has been tempered by the recognition that selegiline can reduce or reverse symptoms but not necessarily affect the progression of the disease. So although selegiline's symptomatic actions can contribute to the delay in need for levodopa, it does not clearly alter progression of the disease once levodopa is started. A large British study suggested that selegiline increased mortality rates, but this finding has not been replicated. Thus, the protective actions of selegiline are controversial. In current clinical practice, selegiline is more commonly used in patients early in the disease and withdrawn later in the course when patients are on multiple antiparkinsonian drugs. It can cause confusion, dyskinesia, orthostatic hypotension, and nausea. Despite the uncertainties that surround selegiline, the search for protective therapies continues with investigations of agents to reduce free-radical formation and damage in the basal ganglia, of glutamate antagonists to reduce excitotoxicity, and of mitochondrial electron chain cofactors to enhance neuronal energy production. Thalamotomy is increasingly used for disabling rest or postural tremor that is unresponsive to pharmacological management. Unilateral thalamotomies abolish or greatly reduce contralateral tremor but do not affect the other parkinsonian signs of rigidity and bradykinesia. Bilateral procedures are associated with a high incidence of dysarthria, dysphagia, and disequilibrium, and they are only reluctantly used in severely affected patients. A new approach is to implant stimulating electrodes in the thalamus, because high-frequency stimulation will inactivate neurons in the vicinity of the electrode tip and produce a reversible thalamotomy. Adverse effects can be minimized by altering the stimulation parameters, and bilateral procedures can be done without the concern of irreversible dysarthria, dysphagia, and disequilibrium. The drawbacks are the expense of the stimulator, the periodic need for battery replacement, and the considerable effort required to find the optimal stimulation parameters. A common compromise is to do a thalamotomy on the first side and, if needed, thalamic stimulation on the contralateral side at a later date. Pallidotomy ameliorates contralateral levodopa-induced dyskinesia. It may also improve other aspects of parkinsonism, but severe dyskinesia is the major indication for the procedure. The adverse effects of bilateral pallidotomies are similar to those of bilateral thalamotomies and are therefore rarely performed. Unilateral and bilateral stimulation of the pallidum and subthalamic nucleus are promising, safer techniques that are under intense investigation for treatment of parkinsonism.